Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update
-
5E Advanced Materials Publishes Fort Cady Project SK-1300 Pre-Feasibility Technical Report with a US$724.8M Pre-Tax NPV7, 19.2% IRR, Initial 39.5-Year Mine Life
-
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
-
Aston Bay and American West Metals Announce New Copper Intersections at the Storm Project, Nunavut, Canada
-
Axcap Continues to Discover New High Grade Zones at Converse
-
Onex Reports Second Quarter 2025 Results
-
Thermon Reports First Quarter Fiscal 2026 Results
-
Backblaze Announces $10 Million Share Repurchase Program
-
North Shore Announces Non-Brokered Private Placement
-
LENSAR Reports Second Quarter 2025 Results and Provides Business Update
-
Nextech3D.ai Achieves Major AI Breakthrough: Simultaneous Generation of 100 Photorealistic 3D Models
-
Salomon Brothers: Addressing Crypto's Wallet Problem
-
Kalo Gold Advances Exploration at Vatu Aurum Project, Fiji
-
Announcing the 2025 Ottawa Consumer Choice Award Winners
-
U.S. Polo Assn. Named No. 1 Sports Licensor and Top 25 on License Global' Prestigious ‘Top Global Licensors’ List
-
Smile Digital Health Maintains Key Certifications in Security, Privacy, and Compliance
-
Microbix Schedules Release of Results for Q3 Fiscal 2025 Results Release and Webinar Discussion on Morning of August 14, 2025
-
Supremex Announces Results for the Second Quarter of 2025, a Special Dividend of $0.50 Per Common Share, the Renewal of Its Normal Course Issuer Bid and Completes Two Tuck-In Acquisitions Subsequent
-
Visible Copper Mineralization in Drill Core and Rock Samples Up to 26% Copper and 5.73 Grams Per Tonne Gold at Yukon Metals’ AZ Property
-
KVH Industries Reports Second Quarter 2025 Results
-
Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
-
Liberty Latin America Reports Q2 and H1 2025 Results
-
BioLineRx to Report Second Quarter 2025 Results on August 14, 2025
-
REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
-
Vistra Reports Second Quarter 2025 Results
-
TeleMate Pushes Boundaries by Reimagining UC&C Observability
-
Starwood Property Trust Reports Results for Quarter Ended June 30, 2025
-
Ultralife Corporation Reports Second Quarter Results
-
Advantage Solutions Reports Second Quarter 2025 Results
-
Crocs, Inc. Reports Solid Second Quarter 2025 Results Led By Both Brands
-
Better Home & Finance Holding Company Announces Second Quarter 2025 Results
-
Papa Johns Announces Second Quarter 2025 Financial Results
-
Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance
-
Altice USA Reports Second Quarter 2025 Results
-
First Student Sets New Safety Standard in Student Transportation Training
-
Are You A Paducah, Kentucky Investor Whose Stifel Broker Sold You Easterly ROCMuni High Income Fund?
-
Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency¹)
-
ALi Corporation and Ceva Announce Strategic Collaboration to Bring Scalable Edge AI to Next-Gen Video Platforms
-
Arbe Announces Q2 2025 Financial Results
-
Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
-
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
-
Backblaze Announces Strong Second Quarter 2025 Financial Results
-
D-Wave Reports Second Quarter 2025 Results
-
Aurora to Participate in Canaccord Genuity 45th Annual Growth Conference
-
Kingsoft Cloud to Report Second Quarter 2025 Financial Results on August 20, 2025
-
CCMP Growth Advisors Acquires HVAC and Plumbing Installation Services Provider Airo Mechanical
-
N-able Announces Second Quarter 2025 Results
-
Warner Bros. Discovery Reports Second Quarter 2025 Results
-
The Tile Shop Reports Second Quarter 2025 Results
-
Palleon Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of E-602 (HLX79), a Potential First-In-Class Treatment for Active Glomerulonephritis
